Gastroenterologìa (Sep 2022)

Rational choice of hepatoprotectors for drug-induced liver injury

  • H.V. Osyodlo,
  • M.P. Boichak,
  • O.O. Fedorova

DOI
https://doi.org/10.22141/2308-2097.56.3.2022.507
Journal volume & issue
Vol. 56, no. 3
pp. 179 – 189

Abstract

Read online

The article deals with a review of the current literature on the clinical use of hepatoprotectors in drug-induced liver injury. The literature was searched in Scopus, Web of Science, PubMed and other databases. Risk factors, pathogenetic mechanisms of li­ver damage, international diagnostic criteria and treatment for drug-induced liver injuries are considered. Clinical and pharmacological approaches to the choice of hepatoprotectors for the management of drug-induced liver injury are substantiated. The positive effects of ademetionine, a hepatoprotector, are highlighted — choleretic, cholekinetic, regenerating, antioxidant and antitoxic. In accordance with the principles of evidence-based medicine, it has been found that the indisputable advantage of ademetionine in the comprehensive treatment of drug-induced liver injury is its high clinical effectiveness as a mean of pathogenetic treatment of cholestasis, hepatocellular lesions and their combinations.

Keywords